Literature DB >> 26549669

Implementing the Surgical Apgar Score in patients with trauma hip fracture.

Sanja Sakan1, Daniela Bandic Pavlovic2, Milan Milosevic3, Igor Virag2, Petar Martinovic2, Ivan Dobric4, Slavko Davila4, Mladen Peric2.   

Abstract

BACKGROUND: Trauma hip fractures in elderly patients are associated with high postoperative long-term morbidity and mortality and premature death. The high mortality in these patients can be explained by various factors, including the fracture itself; the preoperative poor condition and comorbidities of these patients; the influence of stressors, such as surgery and type of anaesthesia, on the patient's condition; and the postoperative development of major complications, such as cardiac failure, pulmonary embolism, pneumonia, deep venous thrombosis and acute renal failure. Thus, the Surgical Apgar Score (SAS) could be a valuable tool for objective risk stratification of patients immediately after surgery, and to enable patients with higher risk to receive postoperative ICU care and good management both during and after the hospital stay.
METHODS: The SAS was calculated retrospectively from the handwritten anaesthesia records of 43 trauma hip fracture patients treated operatively in the University Hospital Centre Zagreb over a 1-year period. The primary endpoints were the 30-days major postoperative complications and mortality, length of the ICU and hospital stay, and 6-months major complications development. Statistical analysis was applied to compare SAS with the patients' perioperative variables.
RESULTS: A SAS≤4 in the trauma hip fracture patients was a significant predictor for the 30-days major postoperative complications with 80% specificity (95% CI: 0.587-0.864, p=0.0111). However, the SAS was not significant in the prediction of 30-days mortality (95% CI: 0.468-0.771, p=0.2238) and 6-months mortality (95% CI: 0.497-0.795, p=0.3997) as primary endpoints in the hip fracture surgery patients.
CONCLUSION: The SAS shows how intraoperative events affect postoperative outcomes. Calculating the SAS in the operating theatre provides immediate, reliable, real-time feedback information about patient postoperative risk. The results of this study indicate that all trauma hip fracture patients with SAS≤4 should go to the ICU postoperatively and should be under intensive surveillance both during the hospital stay and after hospital discharge.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaesthesia; Hip fracture; Intensive care; Surgical Apgar Score; Surgical outcome; Trauma

Mesh:

Year:  2015        PMID: 26549669     DOI: 10.1016/j.injury.2015.10.051

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  4 in total

Review 1.  The Reliability of Surgical Apgar Score in Predicting Immediate and Late Postoperative Morbidity and Mortality: A Narrative Review.

Authors:  Abhijit Nair; Aanchal Bharuka; Basanth Kumar Rayani
Journal:  Rambam Maimonides Med J       Date:  2018-01-29

2.  Osteoporotic hip fracture-Comorbidities and factors associated with in-hospital mortality in the elderly: A nine-year cohort study in Brazil.

Authors:  Viviane Cristina Uliana Peterle; Maria Rita Carvalho Garbi Novaes; Paulo Emiliano Bezerra Junior; João Carlos Geber Júnior; Rodrigo Tinôco Magalhães Cavalcante; Jurandi Barrozo da Silva Junior; Ray Costa Portela; Ana Patricia de Paula
Journal:  PLoS One       Date:  2022-08-12       Impact factor: 3.752

3.  One-Year Outcome of Geriatric Hip-Fracture Patients following Prolonged ICU Treatment.

Authors:  Daphne Eschbach; Christopher Bliemel; Ludwig Oberkircher; Rene Aigner; Juliana Hack; Benjamin Bockmann; Steffen Ruchholtz; Benjamin Buecking
Journal:  Biomed Res Int       Date:  2016-01-13       Impact factor: 3.411

4.  Prediction of perioperative complications after robotic-assisted radical hysterectomy for cervical cancer using the modified surgical Apgar score.

Authors:  Seon Hee Park; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim
Journal:  BMC Cancer       Date:  2018-09-21       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.